Terms: = Prostate cancer AND WHSC1, 7468, O96028, WHS, TRX5, REIIBP, NSD2, MMSET, MGC176638, KIAA1090, FLJ23286
17 results:
1. Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
Kanaoka S; Okabe A; Kanesaka M; Rahmutulla B; Fukuyo M; Seki M; Hoshii T; Sato H; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
Cancer Lett; 2024 Apr; 588():216815. PubMed ID: 38490329
[TBL] [Abstract] [Full Text] [Related]
2. Association of whsc1/nsd2 and T-cell infiltration with prostate cancer metastasis and prognosis.
Li Q; Zhu J; Zhang Y; Pan Y; Li Z; Wang M; Gao Y; Feng D; He X; Zhang C
Sci Rep; 2023 Dec; 13(1):21629. PubMed ID: 38062230
[TBL] [Abstract] [Full Text] [Related]
3. The role of NSD1, nsd2, and NSD3 histone methyltransferases in solid tumors.
Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
[TBL] [Abstract] [Full Text] [Related]
4. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract] [Full Text] [Related]
5. whsc1/nsd2 regulates immune infiltration in prostate cancer.
Want MY; Tsuji T; Singh PK; Thorne JL; Matsuzaki J; Karasik E; Gillard B; Cortes Gomez E; Koya RC; Lugade A; Odunsi K; Battaglia S
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589522
[TBL] [Abstract] [Full Text] [Related]
6. The prognostic impact of tumour nsd2 expression in advanced prostate cancer.
Stangl-Kremser J; Lemberger U; Hassler MR; Garstka N; Grubmüller B; Haitel A; Enikeev DV; Glybochko PV; Kramer G; Susani M; Shariat SF
Biomarkers; 2020 May; 25(3):268-273. PubMed ID: 32091270
[No Abstract] [Full Text] [Related]
7. Integrative Exome Sequencing Analysis in Castration-Resistant prostate cancer in Chinese Population.
Hao L; Li H; Zhang S; Yang Y; Xu Z; Zhang Y; Liu Z
Curr Pharm Biotechnol; 2020; 21(2):140-148. PubMed ID: 31580249
[TBL] [Abstract] [Full Text] [Related]
8. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
9. nsd2 is a conserved driver of metastatic prostate cancer progression.
Aytes A; Giacobbe A; Mitrofanova A; Ruggero K; Cyrta J; Arriaga J; Palomero L; Farran-Matas S; Rubin MA; Shen MM; Califano A; Abate-Shen C
Nat Commun; 2018 Dec; 9(1):5201. PubMed ID: 30518758
[TBL] [Abstract] [Full Text] [Related]
10. Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (mmset) in prostate cancer Cells.
White-Al Habeeb NM; Garcia J; Fleshner N; Bapat B
Prostate; 2016 Dec; 76(16):1507-1518. PubMed ID: 27404348
[TBL] [Abstract] [Full Text] [Related]
11. Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.
Nalla AK; Williams TF; Collins CP; Rae DT; Trobridge GD
Mol Carcinog; 2016 Nov; 55(11):1761-1771. PubMed ID: 26512949
[TBL] [Abstract] [Full Text] [Related]
12. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]
13. Characterization of the EZH2-mmset histone methyltransferase regulatory axis in cancer.
Asangani IA; Ateeq B; Cao Q; Dodson L; Pandhi M; Kunju LP; Mehra R; Lonigro RJ; Siddiqui J; Palanisamy N; Wu YM; Cao X; Kim JH; Zhao M; Qin ZS; Iyer MK; Maher CA; Kumar-Sinha C; Varambally S; Chinnaiyan AM
Mol Cell; 2013 Jan; 49(1):80-93. PubMed ID: 23159737
[TBL] [Abstract] [Full Text] [Related]
14. The histone methyltransferase mmset/whsc1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
Ezponda T; Popovic R; Shah MY; Martinez-Garcia E; Zheng Y; Min DJ; Will C; Neri A; Kelleher NL; Yu J; Licht JD
Oncogene; 2013 Jun; 32(23):2882-90. PubMed ID: 22797064
[TBL] [Abstract] [Full Text] [Related]
15. Histone methyltransferase nsd2/mmset mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
[TBL] [Abstract] [Full Text] [Related]
16. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National cancer Institute Breast and prostate cancer Cohort Consortium (BPC3).
Canzian F; Kaaks R; Cox DG; Henderson KD; Henderson BE; Berg C; Bingham S; Boeing H; Buring J; Calle EE; Chanock S; Clavel-Chapelon F; Dossus L; Feigelson HS; Haiman CA; Hankinson SE; Hoover R; Hunter DJ; Isaacs C; Lenner P; Lund E; Overvad K; Palli D; Pearce CL; Quiros JR; Riboli E; Stram DO; Thomas G; Thun MJ; Trichopoulos D; van Gils CH; Ziegler RG
BMC Cancer; 2009 Jul; 9():257. PubMed ID: 19640273
[TBL] [Abstract] [Full Text] [Related]
17. The histone methyltransferase, nsd2, enhances androgen receptor-mediated transcription.
Kang HB; Choi Y; Lee JM; Choi KC; Kim HC; Yoo JY; Lee YH; Yoon HG
FEBS Lett; 2009 Jun; 583(12):1880-6. PubMed ID: 19481544
[TBL] [Abstract] [Full Text] [Related]
